|Application ||WB, ICC, E|
|Description||ERBB3, v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian). It is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Amplification of this gene and/or overexpression of its protein have been reported in numerous cancers, including prostate, bladder, and breast tumors. Alternate transcriptional splice variants encoding different isoforms have been characterized. One isoform lacks the intermembrane region and is secreted outside the cell. This form acts to modulate the activity of the membrane-bound form. Additional splice variants have also been reported, but they have not been thoroughly characterized.|
|Immunogen||Purified recombinant extracellular fragment of human ERBB3 (aa22-369) fused with hIgGFc tag expressed in HEK293 cells.|
|Formulation||Ascitic fluid containing 0.03% sodium azide.|
|Other Names||Receptor tyrosine-protein kinase erbB-3, 18.104.22.168, Proto-oncogene-like protein c-ErbB-3, Tyrosine kinase-type cell surface receptor HER3, ERBB3, HER3|
|Dilution||WB~~1/500 - 1/2000|
IF~~1/200 - 1/1000
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||ERBB3 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Binds and is activated by neuregulins and NTAK. May also be activated by CSPG5.|
|Cellular Location||Isoform 1: Cell membrane; Single-pass type I membrane protein|
|Tissue Location||Epithelial tissues and brain.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1. Cancer Sci. 2007 Sep;98(9):1498-503. 2. Breast Cancer Res. 2008;10(1):R2.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.